It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The role of angiotensin receptor blocker in wound healing and cutaneous fibrosis has become a hotspot in recent years. We have developed a losartan cream that is comparable to triamcinolone ointment in inhibiting scarring. Considering the effects of chitosan and asiaticoside on wound healing and scarring, we added them to the losartan cream this time and improved the formula, expecting to get a better anti-scarring effect. The effects of creams were investigated on mouse scar model with triamcinolone ointment, onion extract gel, and commercial asiaticoside cream set as positive controls. A preliminary exploration of the mechanism involved in TGF-β/Smad pathway was performed in vivo and in vitro. With all results of anti-scarring, the compound losartan cream (containing chitosan, asiaticoside, and losartan) shows the best effect, followed by the chitosan asiaticoside cream. The treatment of the compound losartan cream inhibited expression of TGF-β1, collagen, and Smads, and decreased phosphorylation of Smad in vivo. These inhibitory effects were also confirmed in vitro. Our findings indicated that the compound losartan cream could inhibit scarring via TGF-β/Smad pathway. This cream might be an effective option for scar treatment.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Zhejiang University School of Medicine, Department of Plastic Surgery, Sir Run Run Shaw Hospital, Hangzhou, People’s Republic of China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
2 Zhejiang University School of Medicine, Department of Plastic Surgery, Sir Run Run Shaw Hospital, Hangzhou, People’s Republic of China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X); Zhejiang University, Institute of Pharmaceutics, College of Pharmaceutical Sciences, Hangzhou, People’s Republic of China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
3 Zhejiang University School of Medicine, Department of Plastic Surgery, The Fourth Affiliated Hospital, Yiwu, People’s Republic of China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)
4 Zhejiang University City College, School of Medicine, Hangzhou, People’s Republic of China (GRID:grid.13402.34) (ISNI:0000 0004 1759 700X)